A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

To be considered for this study, you must have been recently diagnosed with multiple myeloma and have already received a specific type of initial treatment. This includes receiving 3 to 6 cycles of induction therapy (which is typically a combination of medicines like proteasome inhibitors and immunomodulatory drugs, sometimes with another drug called a CD38 monoclonal antibody) and then had a stem cell transplant. You also need to have shown a good response to these treatments, meaning your myeloma has improved, and it must be within 12 to 15 months since you started your initial treatment.

You would not be able to join the study if your myeloma has started to get worse after your stem cell transplant, or if it didn't respond well to your primary treatment. Also, certain other conditions would prevent you from taking part, such as if your myeloma has spread to the brain or spinal cord, or if you have had other cancers in the last five years. The study team will check all your medical details carefully to make sure it's safe and appropriate for you to participate.

If you join this study, you will be given either Iberdomide or Lenalidomide as your maintenance treatment after your stem cell transplant. You will likely take the medication regularly, as prescribed by the study doctors. You will have regular hospital visits for check-ups, blood tests, and to assess how you are responding to the treatment and to monitor for any side effects. These visits will continue for a set period and the total duration varies to ensure thorough monitoring and data collection.